BTLA and Sepsis: The use of cytokines such as interleukin-7 (IL-7), interleukin-15 (IL-15), granulocyte-macrophage colony-stimulating factor (GM-CSF) and co-inhibitory molecules blockade involving anti-programmed cell death receptor-1 (anti-PD-1) and anti-B and T lymphocyte attenuator (anti-BTLA) have been proven to reduce the mortality of sustained sepsis (Leentjens et al., 2013; Hutchins et al., 2014; Delano and Ward, 2016; van der Poll et al., 2017; Venet and Monneret, 2018; Steinhagen et al., 2020).